THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH Patent applications |
Patent application number | Title | Published |
20160113518 | MICROCHIP SENSOR FOR CONTINUOUS MONITORING OF REGIONAL BLOOD FLOW - A sensor is provided available for continuous monitoring of regional blood flow in a tissue, including cerebral tissue. Methods of monitoring regional blood flow using the sensor as well as systems and computer readable medium therefor are also provided. | 04-28-2016 |
20150361058 | INHIBITION OF MACROPHAGE MIGRATION INHIBITORY FACTOR IN MELANOMA AND COLON CANCER - Compounds and compositions are provided which inhibit MIF. Methods of treatment of melanoma and colon cancers are also provided. | 12-17-2015 |
20150335763 | HMGB1-BINDING BEADS AND USES THEREOF - Disclosed are therapeutic beads comprising agents, such as nucleic acids, that bind to high mobility group box 1 (HMGB1) and methods of treating subjects with conditions that would benefit from reducing the deleterious effects of HMGB1, such as inflammatory bowel diseases, comprising administering the beads to the gastrointestinal tract of the subjects. | 11-26-2015 |
20150104472 | C1q PEPTIDES AND USES THEREOF - Isolated C1q peptides, fusion proteins and compositions comprising such and fusion proteins comprising are provided. Isolated fusion proteins comprising X | 04-16-2015 |
20150023957 | SAA DOMAIN-SPECIFIC ANTIBODIES AND PEPTIDE ANTAGONISTS AND USE THEREOF TO TREAT INFLAMMATORY DISEASES - Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided. | 01-22-2015 |
20140350380 | IDENTIFICATION AND USES OF BRAIN ACTIVITY NETWORKS - Methods for identifying networks correlating with placebo effects, progression of neurological disease symptoms, progression of pre-phenoconversion states of neurological diseases, and efficacious/non-efficacious candidate treatments for neurological diseases are provided. | 11-27-2014 |
20140342988 | ADRENOMEDULLIN AND ADRENOMEDULLIN BINDING PROTEIN FOR ISCHEMIA/REPERFUSION TREATMENT - Methods of treating a mammal at risk for ischemia-reperfusion injury are provided. The methods comprise administrating an adrenomedullin binding protein-1 (AMBP-1) to the mammal in sufficient amount to reduce the injury. Also provided are methods of treating a mammal at risk for ischemia-reperfusion injury to the bowel. The methods comprise administering adrenomedullin to the mammal in sufficient amount to reduce the injury. | 11-20-2014 |
20140336476 | MICROCHIP SENSOR FOR CONTINUOUS MONITORING OF REGIONAL BLOOD FLOW - A sensor is provided available for continuous monitoring of regional blood flow in a tissue, including cerebral tissue. Methods of monitoring regional blood flow using the sensor as well as systems and computer readable medium therefor are also provided. | 11-13-2014 |
20140336256 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS - The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is expressly contemplated. | 11-13-2014 |
20140323576 | METHOD FOR TREATING GLIOBLASTOMAS AND OTHER TUMORS - Methods of treating an astrocytoma with agents effective to inhibit microglia function are provided, as well as methods of enhancing the efficacy of brain tumor radiation therapy on an astrocytoma in a subject. Also provided are methods of treating other solid tumor types, and tumor cell invasion, with guanylhydrazone compounds. | 10-30-2014 |
20140309255 | COMPOUNDS AND METHODS FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - Small molecule compounds are provided for treating lupus as are methods of treating lupus using these compounds. | 10-16-2014 |
20140242091 | METHOD FOR TREATING PATHOLOGIES ASSOCIATED WITH HYPOXIA USING MIF INHIBITORS - Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for reating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided. | 08-28-2014 |
20140213954 | TOE PROTECTING CUSHION DEVICE - Toe cushioning device for protecting a patient's toes. A toe cushion device includes two tubular cushions positioned in a transverse plane on the plantar side of a patient's toes during use. The toe cushion relieves foot or toe pain and conforms to the changing contour of the patient's foot and toes during use. | 07-31-2014 |
20140194937 | FASTENER - A fastener includes an elongate fastener body defining a longitudinal axis substantially central thereto. The fastener body has a continuous outer fastener shell laterally surrounding the longitudinal axis. The fastener shell longitudinally separates a fastener head end and a fastener tip end. A tool-engaging feature is provided on the fastener head end. A plurality of teeth are located on the fastener shell and extend substantially laterally outward from the longitudinally axis. The fastener shell is comprised of at least one undulate face and at least one substantially flat face. The plurality of teeth are located only on the undulate faces. Each tooth is longitudinally separated from adjacent teeth along an undulate face. A method of installing the fastener into a receiving structure is also described. | 07-10-2014 |
20140193412 | TREATMENT OF CUTANEOUS WOUNDS BY INHIBITING COLD SHOCK PROTEINS - Disclosed are methods of treating a subject suffering from a cutaneous wound comprising administering to the subject a CIRP inhibitor. | 07-10-2014 |
20140186353 | Treatment Of Inflammatory Diseases By Inhibiting Cold-Inducible RNA-Binding Protein (CIRP) - Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor is also described herein. | 07-03-2014 |
20140128692 | FLEXIBLE SPIRALLY-ROLLED POLYMER TUBE FOR MONITORING AND TREATMENT OF BRAIN INJURIES - A flexible spirally-rolled polymer microtube for in vivo monitoring and treatment of brain injuries; the tube integrally comprising one or more microsensors and one or more microchannels, wherein the microsensors monitor one or more parameters and the microchannels are capable of delivering substances to the brain, removing substances from the brain, or both. | 05-08-2014 |
20140069591 | PRIVACY CURTAIN ASSEMBLY WITH CLEANABLE PANELS - A privacy curtain assembly includes a main curtain portion. The main curtain portion includes a first side, a second side, and oppositely disposed leading edges located between the first and second sides. The privacy curtain assembly also includes at least one cleanable, wipable panel that is permanently affixed to one of the leading edges of the main curtain portion. The at least one panel is configured to be cleaned while permanently affixed to the main curtain portion. | 03-13-2014 |
20130190369 | MODIFIED MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS - Provided are various compounds of Formula I (I). Also provided are various compounds of Formula II (II). Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor. | 07-25-2013 |
20130123299 | COMPOUNDS AND METHODS FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - Small molecule compounds are provided for treating lupus as are methods of treating lupus using these compounds. | 05-16-2013 |
20130115217 | ANTIBODIES AGAINST HMGB1 AND FRAGMENTS THEREOF - In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to particular fragments of HMGB1, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade, methods of detecting and/or identifying an agent that binds to an HMGB1 polypeptide or fragment thereof, and methods of detecting HMGB1 in a sample. | 05-09-2013 |
20130096048 | TREATMENT OF SEPSIS AND SEPTIC SHOCK USING GHRELIN AND GROWTH HORMONE - Methods are disclosed for treating sepsis and septic shock using a combination of ghrelin and growth hormone, and for using ghrelin to reduce organ and tissue injury and improve survival after combined radiation exposure and sepsis. | 04-18-2013 |
20130071389 | METHODS FOR TREATMENT OF INFLAMMATORY DISEASES - The present invention provides methods of treating inflammatory diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits pigment epithelium-derived factor (PEDF) and methods of screening for agents that inhibit PEDF. | 03-21-2013 |
20130028910 | HMG1 ANTIBODY FOR TREATING INFLAMMATORY CONDITIONS - There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a phamaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment. | 01-31-2013 |
20120322719 | METHODS OF TREATMENT OF FATTY LIVER DISEASE BY PHARMACOLOGICAL ACTIVATION OF CHOLINERGIC PATHWAYS - A method of treating a fatty liver disease in a subject. The method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis, and alcoholic cirrhosis. | 12-20-2012 |
20120219546 | METHODS FOR TREATING CONDITIONS MEDIATED BY THE INFLAMMATORY CYTOKINE CASCADE USING GAPDH INHIBITORS - The present invention is directed to a method of treating a subject at risk for or having a condition mediated by an inflammatory cytokine cascade comprising administering to the subject an amount of a GAPDH inhibitor effective to treat the subject at risk for or having a condition mediated by an inflammatory cytokine cascade. | 08-30-2012 |
20120128586 | METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA - The present invention provides a method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the proliferative compartment of a CLL clone of the subject to treat chronic lymphocytic leukemia in the subject. The present invention also provides a method for treating a subject having chronic lymphocytic leukemia comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the “resting re-entry compartment” to treat chronic lymphocytic leukemia in the subject. | 05-24-2012 |
20110268695 | USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS - Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade. | 11-03-2011 |
20110245286 | TREATMENT OF INFLAMMATION USING ALPHA 7 RECEPTOR-BINDING AGONISTS - Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for inhibiting an inflammatory cytokine cascade in a patient are also provided. The methods comprise treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for determining whether a compound is a cholinergic agonist reactive with an α7 nicotinic receptor are also provided. The methods comprise determining whether the compound inhibits release of a proinflammatory cytokine from a mammalian cell. Additionally, methods for determining whether a compound is a cholinergic antagonist reactive with an α7 nicotinic receptor are provided. These methods comprise determining whether the compound reduces the ability of a cholinergic agonist to inhibit the release of a proinflammatory cytokine from a mammalian cell. Oligonucleotides or mimetics capable of inhibiting attenuation of lipopolysaccharide-induced TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are also provided. The oligonucleotides or mimetics consist essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 receptor. Additionally, methods of inhibiting attenuation of TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are provided. These methods comprise treating the macrophage with the above-described oligonucleotide or mimetic. | 10-06-2011 |
20110236406 | IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES - The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specifically, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation. | 09-29-2011 |
20110166148 | TREATMENT OF INFLAMMATION USING ALPHA 7 RECEPTOR-BINDING CHOLINERGIC AGONISTS - A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein. | 07-07-2011 |
20110136911 | TREATMENT OF SEPSIS AND INHIBITION OF MIF BY D-T4 - Methods and compositions are disclosed for the use of dextrothyroxine (D-T4) to treat sepsis, inflammation, and conditions and diseases in which it is desirable to inhibit macrophage migration inhibitory factor (MIF). | 06-09-2011 |
20110091867 | METHOD TO IDENTIFY AND PREDICT DISEASE PROGRESSION OF HUMAN PAPILLOMA VIRUS-INFECTED LESIONS - The present invention provides a method for distinguishing benign human papilloma virus (HPV)-infected tissue from HPV-related lesions that have undergone malignant transformation. In one embodiment, the invention comprises a simple histochemical staining method and details a novel process for examining HPV-infected cells by determining susceptibility to enzymatic DNA digestion. Residual virion-associated DNA is seen only in benign HPV-infected lesions, while absence of residual DNA is seen with malignant transformation. In another embodiment, the invention comprises immunohistochemical assay methods for examining HPV-infected cells, utilizing antibodies to HPV L1 proteins. These methods can be used to predict biologic behavior of HPV-infected lesions. The invention can improve current cervical cancer screening programs, and improve clinical management of patients by defining malignant potential of HPV-infected tissue more accurately. | 04-21-2011 |
20100303813 | BIOMARKERS FOR PREDICTING ANTI-TNF RESPONSIVENESS OR NON-RESPONSIVENESS - The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder. | 12-02-2010 |
20100172905 | ANTAGONISTS OF HMG1 FOR TREATING INFLAMMATORY CONDITIONS - There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment. | 07-08-2010 |
20090324588 | Treating Inflammatory Disorders With Antibodies to the Alpha-7 Nicotinic Receptors - An antibody or an antigen binding fragment thereof which binds to mammalian α7 subunit of a nicotinic acetylcholine receptor or its functional variant and which is an agonist of said receptor or variant. Pharmaceutical compositions comprising same. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject an antibody or an antigen-binding fragment as described herein. | 12-31-2009 |
20090170951 | Phenolic Hydrazone Macrophage Migration Inhibitory Factor Inhibitors - Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor. | 07-02-2009 |
20080305120 | Immunogenic Compositions Comprising Hmgb 1 Polypeptides - The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specially, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation. | 12-11-2008 |
20080305118 | Treatment Of Type 1 Diabetes With Inhibitors Of Macrophage Migration Inhibitory Factor - Methods of treating a mammal having type 1 diabetes or a risk for type 1 diabetes are provided. The methods comprise administering to the mammal a pharmaceutical composition comprising an agent that inhibits MIF in the mammal. Also provided are methods of evaluating whether a compound is useful for preventing or treating type 1 diabetes. The methods comprise determining whether the compound inhibits a macrophage migration inhibitory factor (MIF) in a mammal, then, if the compound inhibits the MIF, determining whether the compound inhibits development of type 1 diabetes. | 12-11-2008 |